Background
==========

Extranodal NK/T-cell lymphoma of nasal type (ENKTL) is difficult to diagnose, is highly invasive, and exhibits poor sensitivity to chemotherapy \[[@b1-medscimonit-22-4297]\]. ENKTL is likely to relapse despite treatments and distant metastases are often observed, resulting in poor prognosis. The geographical distribution of ENKTL differs significantly, and it is far more common in Asia, Central America, and South America compared with other parts of the world \[[@b2-medscimonit-22-4297],[@b3-medscimonit-22-4297]\]. In 2010, ENKTL was reported to account for 6.9% of all non-Hodgkin's lymphoma (NHL) in China, and accounted for 28.2% of T cell and NK cell lymphomas \[[@b4-medscimonit-22-4297]\].

Although the disease manifests itself as focal lesions in about two-thirds of ENKTL patients, prognosis is still poor \[[@b5-medscimonit-22-4297]\]. Currently, there is no internationally recognized first-line chemotherapy regimen for ENKTL. The traditional treatment protocols include radiotherapy, chemotherapy, and comprehensive therapy (radiotherapy + chemotherapy), but the 3-year overall survival (OS) is only 40--50%, even in patients with stage I/II focal lesions \[[@b6-medscimonit-22-4297]--[@b8-medscimonit-22-4297]\], suggesting that the traditional cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based regimens fail to achieve a satisfactory efficacy. Therefore, the selection of appropriate treatment regimens for ENKTL remains a clinical challenge.

Combined chemo-radiotherapy, shortened chemotherapy intervals, and high-intensity regimens have been reported to improve the prognosis of patients with ENKTL, but no study has reported the specific number of courses of chemotherapy associated with the best efficacy, and clinicians have to rely on their personal experience. Most published studies of ENKTL chemotherapy efficacy applied ≤6 courses of chemotherapy combined with radiotherapy, but the relapse rate can still be as high as 50% \[[@b9-medscimonit-22-4297]\].

L-asparaginase-based combination chemotherapy regimen of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE regimen) and radiotherapy have been recommended \[[@b10-medscimonit-22-4297]\], but long-term follow-up revealed that asparaginase may induce significant adverse effects, including hypofibrinogenemia and acute pancreatitis, and this regimen is still associated with a high long-term relapse rate \[[@b11-medscimonit-22-4297]\]. Reports have confirmed that increasing the number of chemotherapy courses might affect the efficacy and long-term survival of diffuse large B lymphoma \[[@b12-medscimonit-22-4297],[@b13-medscimonit-22-4297]\], but it is still unknown whether these results are applicable to other pathological types of NK/T lymphoma. The lack of prospective studies limits the possibility of selecting an appropriate number of courses of chemotherapy to optimize the relapse rate.

Therefore, this retrospective study aimed to investigate whether chemotherapy regimens with increased courses and dose intensity in young patients (\<60 years old) with ENKTL can improve efficacy, relapse, and survival. These results could help providing guidance for clinical chemotherapy.

Material and Methods
====================

Patients
--------

This single-center retrospective cohort study included 69 patients treated at the Department of Hematology of the Second Affiliated Hospital of Xi'an Jiaotong University between January 2004 and December 2013. Inclusion criteria were: 1) \<60 years old; 2) Eastern Cooperative Oncology Group (ECOG) score of 0--2; and 3) diagnosed with ENKTL according to the diagnostic criteria of the World Health Organization (WHO) Taxonomy of Hemopoiesis and Lympho-Plasmacytic Diseases (2001) \[[@b14-medscimonit-22-4297],[@b15-medscimonit-22-4297]\], which were the current criteria during the study period. Exclusion criteria were: 1) recurrent NHL; 2) secondary lymphoma after chemotherapy or radiotherapy; 3) primary central nervous system (CNS) NHL; 4) human immunodeficiency virus or acquired immunodeficiency syndrome-related lymphoma; 5) malignant tumors after transplantation; 6) severe acute or chronic infection; 7) pregnancy or lactation; 8) psychosis; or 9) dysfunction of the heart, liver, or kidney not associated with chemotherapy. All patients who did not complete the planned treatment were also excluded. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University, and patients or their guardians provided written informed consent.

Data collection
---------------

All patients were comprehensively assessed before chemotherapy, including electrocardiogram, echocardiogram, computed tomography (CT) of the nasal cavity, brain, chest, abdomen, and pelvis, and lymph node B-mode ultrasound of superficial organs.

Chemotherapy
------------

The choice of chemotherapy was made by the treating physician after a comprehensive evaluation of the patient and the disease. Patients who received high-intensity chemotherapy received \>8 courses of improved CHOP (doxorubicin was replaced by pirarubicin, vincristine was replaced by vinorelbine, and oral prednisone was replaced by intravenous injection of dexamethasone); CHOP with additional etoposide (CHOP-E); mitomycin and etoposide alternating with cytarabine and dexamethasone (MAED); mitomycin, methotrexate, and etoposide alternating with dexamethasone (MMED); etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH); SMILE; or hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) regimen \[[@b10-medscimonit-22-4297],[@b16-medscimonit-22-4297]\]. The improved CHOP regimen was preferred in all patients for the induction phase (first year); the delay between courses was 2--4 weeks, according to the patient's condition. The other regimen, with increased dose intensity, were alternatively used in the consolidation phase (years 2--3). The order for the selection of chemotherapy regimen was: CHOP, CHOP-E, EPOCH, MAED, MMED, SMILE, and Hyper-CVAD \[[@b10-medscimonit-22-4297],[@b16-medscimonit-22-4297]\]. Patients receiving the high-intensity regimen underwent at least 8 courses of chemotherapy and a maximum of 16. Based on the recommendations of 6--8 cycles CHOP/RCHOP for diffuse large B-cell lymphoma treatment \[[@b16-medscimonit-22-4297]\] and the use of 1--6 cycles of chemotherapy \[[@b17-medscimonit-22-4297]\], we felt it was appropriate to stratify patients according to the treatment they received, so the patients were divided into 3 groups of \>8 courses (high-intensity group), 6--8 courses, and \<6 courses.

Patients who were not considered for the high-intensity regimen received a maximum of 8 courses of chemotherapy, either CHOP or SMILE \[[@b16-medscimonit-22-4297],[@b17-medscimonit-22-4297]\]. The dose was lowered by 25% in case of life-threatening grade 4 toxicity. For analysis purposes, these patients were further categorized as 6--8 courses and ≤5 courses.

The improved CHOP regimen consisted of 750 mg/m^2^ cyclophosphamide, 30 mg/m^2^ pirarubicin, vinorelbine 25 mg/m^2^, and 10 mg dexamethasone, on days 1 and 8. In the CHOP-E regimen, 100 mg/m^2^ etoposide were added on days 1 and 3. The MAED regimen included 6 mg/m^2^ mitomycin and 100 mg/m^2^ etoposide on days 1 and 3, and 100 mg/m^2^ cytarabine and 10 mg dexamethasone on days 1 and 5. The MMED regimen included 6 mg/m^2^ mitomycin, 100 mg/m^2^ methotrexate, and 100 mg/m^2^ etoposide on days 1 and 3, and dexamethasone 10 mg on days 1 and 5. The EPOCH regimen included 100 mg/m^2^ etoposide added on days 1 and 3, vinorelbine 25 mg/m^2^, 75 mg/m^2^ doxorubicin, and 750 mg/m^2^ cyclophosphamide on days 1 and 8. The SMILE regimen (dexamethasone, methotrexate, ifosfamide, etoposide, and L-asparaginase) was alternated with the A+B regimens of Hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone).

After each course of chemotherapy, the next course was administered after 2 to 4 weeks. If white blood cell counts were \<1.0×10^9^/L or blood platelet counts were 50×10^9^/L, the next course was delayed until the blood cells were restored.

Radiotherapy
------------

Local radiotherapy was performed after 3 courses of chemotherapy in patients stage I--II according to the National Comprehensive Cancer Network (NCCN) guidelines \[[@b10-medscimonit-22-4297],[@b16-medscimonit-22-4297]\]. Intensity-modulated radiation therapy was administered at 54 Gy in 27 fractions, once daily for 5 days.

Symptomatic supportive treatment
--------------------------------

Patients with peripheral blood white blood cell counts less than 2.0×10^9^/L were administered subcutaneous injection of G-CSF. Patients with platelet counts below 50×10^9^/L were administered recombinant human thrombopoietin and hemostatic therapy. When the platelet count fell below 20×10^9^/L or patients exhibited hemorrhage tendency, platelet suspension was infused. Patients with hemoglobin lower than 60 g/L and poor cardiopulmonary compensation were infused with red blood cell suspension. Patients with grade 4 myelosuppression were admitted into a sterile laminar flow ward and were given antibiotics, antifungals, and G-CSF. Patients with high blood Epstein-Barr virus (EBV) DNA titers (\>10^3^ IU/ml) were given ganciclovir and foscarnet \[[@b18-medscimonit-22-4297]\]. Here, it was not indicated that EBV was the evaluator factor for etiology. According to most relevant studies, EBV virus infection worsens the NK/T lymphoma prognosis. So for the patients with EBV virus infection, the administration of antiviral treatment is necessary and is beneficial to improve long-term survival.

Follow-up
---------

Outpatient follow-up was performed every 3 months for the first 2 years, and then every 6 months. Symptoms, vital signs, survival, and quality of life were recorded. Routine blood tests and liver and kidney function tests were performed, as well as EBV titers, lymphocyte subsets, and electrocardiogram. Assessment of outcomes included measurement of size, number, distribution, and characteristics of lymphomas based on palpation of lymph nodes or lumps, B-ultrasound, X-ray, CT, and positron emission tomography (PET)-CT. This was a retrospective cohort study and all of the available patient data obtained in the study period were enrolled and analyzed. There was no calculation of sample size. In the initial study phase, the patients' data were input into the database, and then the data were arranged and analyzed. Full sets of data were available for all patients and no patient was lost to follow-up. This high degree of compliance reflects the good compliance for tumor patients, the use of a specialized department and hospital, and timely telephone calls to remind the patients to attend follow-up.

Efficacy assessment
-------------------

Short-term efficacy was assessed after 3 courses of therapy, and graded according to the WHO guidelines \[[@b19-medscimonit-22-4297]\] as complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The total remission rate (RR) was calculated as CR+PR, and ineffectiveness rate was calculated as SD+PD. Relapse was defined as the appearance of new lesions (lymph nodes or lumps, or bone marrow infiltration) after complete remission. Long-term efficacy was assessed using OS (defined as the time from start of treatments to death or last follow-up), 5-year progression-free survival (PFS; defined as the time from start of treatments to recurrence or death), 5-year event-free survival (EFS; defined as the time from start of treatments to any event leading to changes in treatments such as severe adverse effects, non-tolerance, disease progression, or death), and relapse during follow-up. All patients lost to follow-up were excluded.

Adverse effects
---------------

According to the chemotherapeutic toxicity grading guidelines issued by the WHO, adverse effects were classified into grade 0 (none), 1 (mild), 2 (moderate), 3 (severe), and 4 (life-threatening), according to the annotation from the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC-AE) 4.0 \[[@b20-medscimonit-22-4297]\].

Statistical analysis
--------------------

The patients were categorized according to high-intensity chemotherapy *vs.* 6--8 courses of chemotherapy *vs.* \<6 courses of chemotherapy. Patients were also stratified by systemic EBV infection (positive *vs.* negative). Continuous variables are presented as mean ± standard deviation and were analyzed using analysis of variance with the Tukey's post hoc test. Categorical variables are presented as frequencies and were analyzed using the Fisher exact test. The Kaplan-Meier method was used to generate survival curves and calculate survival. The log-rank test was used to compare survival among groups. The Cox proportional hazard model was used to analyze the independence of variables in multivariate analysis. Statistical analyses were performed using SPSS 18.0 (IBM, Armonk, NY, USA). Two-sided P-values \<0.05 were considered statistically significant.

Results
=======

Clinical characteristics
------------------------

This was a retrospective study of patients \<60 years old with an ECOG score of 0--2 who received treatment for ENKTL at the Second Affiliated Hospital of Xi'an Jiaotong University between January 2004 and December 2013. A total of 69 patients were enrolled, of which 37 received high-intensity chemotherapy and 32 received conventional chemotherapy (control group). Of those patients in the control group, 18 received 6--8 courses of chemotherapy and 14 received \<6 courses. The demographic and clinical characteristics were similar among all 3 groups (all P\>0.05 by overall comparison) ([Table 1](#t1-medscimonit-22-4297){ref-type="table"}). [Supplementary Table 1](#s1-medscimonit-22-4297){ref-type="supplementary-material"} presents the individual characteristics of each patient.

Short-term efficacy
-------------------

Efficacy was assessed after 3 courses of chemotherapy. In the high-intensity, 6--8 courses, and \<6 courses groups, the RR was 83.8% (31/37), 77.8% (14/18), and 78.6% (11/14), respectively (overall P=0.834); the CR was 73.0% (27/37), 66.7% (12/18), and 64.3% (9/14), respectively (overall P=0.795); and the PR was 10.8% (4/37), 11.1% (2/18), and 11.1% (2/18), respectively (overall P=0.939).

Twenty-two patients tested positive for systemic EBV infection: 12, 5, and 5 in the high-intensity, 6--8 courses, and \<6 courses groups, respectively. CR in the high-intensity group was significantly higher in patients with EBV infection compared to those without (41.7% and 88.0%, P=0.006) ([Table 2](#t2-medscimonit-22-4297){ref-type="table"}). There were no differences between patients with/without active EBV infection in the other 2 groups.

Long-term efficacy
------------------

By September 30, 2014, the median follow-up ranged from 8 to 82 months (mean of 52 months). The high-intensity group received a median of 14 courses of chemotherapy (range: 9--16). The 6--8 courses group received a median of 6 courses (range: 6--8). The \<6 courses group received a median of 3 courses (range: 3--5).

The 5-year OS in the high-intensity, 6--8 courses, and \<6 courses groups was significantly different among groups (63.5% *vs.* 45.1% *vs.* and 22.9%, respectively, overall P=0.030); as well as 5-year PFS (59.1% *vs.* 36.0% *vs.* 15.1%, respectively, overall P=0.020); 5-year EFS (54.1% *vs.* 35.5% *vs.* 12.9%, respectively, overall P=0.022); and relapse rates (37.0% *vs.* 50.0% *vs.* 88.9%, respectively, overall P=0.027) ([Figure 1](#f1-medscimonit-22-4297){ref-type="fig"}). Patients with stage III/IV seem to fare worse than patients with stage I/II, irrespective of chemotherapy, but the small number of patients in stage III/IV preclude any firm conclusions ([Supplementary Figure 1](#s2-medscimonit-22-4297){ref-type="supplementary-material"}).

Of the 22 patients with active EBV infection, only 6 recovered from the infection during follow-up for 3 to 15 months, but all 6 relapsed during follow-up. Eleven end-stage patients showed hemophagocytic syndrome (HLH) and an outbreak process, with rapid deterioration. They all died, within an average of 6 weeks. Ten of the 11 patients who developed HLH were EBV-infected.

The 5-year survival of patients with EBV was lower than that of patients without EBV infection among patients in the high-intensity group (P=0.01), but not in the other 2 groups ([Table 3](#t3-medscimonit-22-4297){ref-type="table"}, [Figure 2](#f2-medscimonit-22-4297){ref-type="fig"}). This difference was also observed when all patients were analyzed together ([Figure 3](#f3-medscimonit-22-4297){ref-type="fig"}). Thirty-three patients died during follow-up: 11 of hemophagocytic syndrome, 16 of disease progression, 3 of heart failure, 2 of respiratory failure, and 1 of liver failure.

Multivariate analysis
---------------------

The multivariate analysis revealed that the total number of chemotherapy courses, the chemotherapy strategy, and NK score were independent prognostic factors affecting OS, PFS, and EFS ([Table 4](#t4-medscimonit-22-4297){ref-type="table"}).

Safety and toxicity
-------------------

The rate of adverse effects was recorded during follow-up, and higher rates of many adverse events were reported in the high-intensity group compared with the other 2 groups ([Table 5](#t5-medscimonit-22-4297){ref-type="table"}). Nevertheless, the reported adverse events were controllable and the main outcomes (including chemotherapy-related mortality) were similar among groups.

Discussion
==========

This was a single-center retrospective cohort study of the outcomes of chemotherapy in patients less than 60 years of age diagnosed with ENKTL. Although the RR did not differ significantly among groups, the 5-year OS, PFS, and DFS were significantly better in patients who received high-intensity chemotherapy, and the RR was significantly lower in this group. The rate of adverse effects did not differ significantly among the 3 groups.

Compared with the traditional CHOP regimens, in our improved CHOP regimen, the doxorubicin was replaced by pirarubicin, vincristine was replaced by vinorelbine, and oral prednisone was replaced by intravenous injection of dexamethasone. The potential advantages of this regimen include: (1) pirarubicin is a synthetic anthracycline antitumor antibiotic. Compared with doxorubicin, the fat solubility of pirarubicin is increased due to structural changes, which enable it to quickly enter cells but be excluded slowly, leading to a high concentration in the cells and increased anti-tumor activity \[[@b21-medscimonit-22-4297]\]. The incidence of cardiac toxicity was 1.5% in elderly NHL patients receiving pirarubicin and 14.2% for those receiving doxorubicin in combination chemotherapy \[[@b22-medscimonit-22-4297]\]. Therefore, it is applicable to more patients, and it is safe in elderly patients. (2) Vinorelbine is a semi-synthetic vinca alkaloid compound with broad-spectrum anti-tumor activity, and has lower neurotoxicity compared with other vinca alkaloids \[[@b23-medscimonit-22-4297]\]. In addition, monotherapy efficiency of vinorelbine can be up to 38% in NHL patients who had received failure treatment with vinca alkaloid chemotherapy drugs \[[@b24-medscimonit-22-4297]\]. (3) Dexamethasone is a long-term glucocorticoid, which can more effectively reduce CNS infiltration or relapse and reduce adverse effects of chemotherapy better than prednisone \[[@b25-medscimonit-22-4297]\]. Furthermore, we produced new combinations of drugs according to different mechanisms, no cross-resistance, and other principles, such as MMED and MAED regimens, as well as produced multidrug resistance genes (MDR), aiming to improve the efficacy in treating hematological malignant tumors.

Yamaguchi et al. performed a long-term follow-up study of the JCOGO211 trial \[[@b26-medscimonit-22-4297]\]. They showed that in 33 stage I/IIE patients (ECOG score 0--2) undergoing radiotherapy and DeVIC chemotherapy, the OS and PFS by Yamaguchi were 70% and 63%, which are similar to the present study (71.1% and 65.6%, respectively). Wang et al. studied 27 patients with newly- diagnosed ENKTL patients receiving the GELOX chemotherapy; after a median follow-up of 27.4 months, OS and PFS were 86% \[[@b27-medscimonit-22-4297]\]. It was previously reported that in patients with ENKTL treated with CHOP-L regimen combined with radiotherapy, the 2-year OS and PFS were 80.1% and 81.0%, respectively \[[@b28-medscimonit-22-4297]\]. In patients with stage I/II ENKTL initially treated with CCRT+DeVIC, the rate of complete remission was 77%, and 2-year OS and PFS were 78% and 67%, respectively \[[@b29-medscimonit-22-4297]\]. In the present study, the 2-year OS and PFS in the high-intensity group were higher, at 91.7% and 86.1%, respectively, which may indicate that increased dose intensity and improved regimens can improve outcome in severe ENKTL. Lee et al. \[[@b9-medscimonit-22-4297]\] compared the efficacy of CCRT (1--6 courses) and SCRT (1--4 courses) treatment modes and found that neither the 3-year OS (59% and 75%, respectively) nor 3-year PFS (41% and 56%, respectively) differed significantly. The long-term efficacy of a longer treatment course in the present study was also higher, in agreement with a previous report by Ma et al. \[[@b30-medscimonit-22-4297]\].

The etiology and pathogenesis of ENKTL are still unclear, but EBV has been implicated \[[@b31-medscimonit-22-4297]\]. Huang et al. \[[@b32-medscimonit-22-4297]\] hypothesized that EBV infection causes active NK cells in the nasal cavity to release cytokines (IL-2, IL-9, and IL-15), which reduce the expression of tumor suppressor genes, leading to malignant conversion of NKC cells and promotion of ENKTL progression. Early studies have confirmed that plasma EBV DNA titers are positively correlated with tumor loading and poor prognosis \[[@b33-medscimonit-22-4297],[@b34-medscimonit-22-4297]\]. Therefore, continuously monitoring EBV levels in peripheral blood may show efficacy and/or act as an early indicator of relapse \[[@b35-medscimonit-22-4297]\]. In this study, the efficacy of treatment in patients with low EBV titers was greater than that in patients with high EBV titers. Appropriately prolonging the course of chemotherapy course was associated with increased survival rate, and EBV became temporarily undetectable in some patients during therapy. Ten patients with EBV-related HLH exhibited quicker progression, shorter survival, and 100% mortality, and the main causes of death were bleeding, infection, failure of multiple organs, and DIC. Cytokines released after EBV infection play an important role in the pathogenesis of EBVHLH \[[@b36-medscimonit-22-4297],[@b37-medscimonit-22-4297]\], causing uncontrolled activation of T lymphocytes and macrophages to attack otherwise healthy cells, causing clinical presentation of the manifestations of HLH.

A large retrospective and multi-center study of 262 patients from South Korea reported that Ann Arbor stage, B symptoms, LDH levels, and regional lymph node involvement were independent prognostic factors in patients with ENKTL \[[@b12-medscimonit-22-4297]\]. Based on these results, they established a prognostic model for patients with ENKTL, and reported that it predicted prognosis of ENKTL patients more accurately than the IPI score. A further study of 105 patients with early ENKTL reported that Ann Arbor staging, IPI score, and tumor invasion were independent prognostic factors of ENKTL \[[@b38-medscimonit-22-4297]\]. Another retrospective study of 79 patients with stage I--IV ENKTL reported that Ann Arbor stage and PS score were associated with ENKTL prognosis \[[@b8-medscimonit-22-4297]\]. In the present study, total number of chemotherapy courses, chemotherapy strategy, and NK score were independent prognostic indexes associated with OS, PFS, and DFS. Clearly, selection of chemotherapy regimen is crucial for ENKTL prognosis. In this study, short-term efficacy and long-term survival were improved using alternating chemotherapy with prolonged courses and improved regimens compared with the traditional regimens, and the reasons may include: (1) The dose was increased in the remission induction phase and administration was focused on the 1^st^ and 8^th^ days. (2) These drugs had synergic effects, which tended to strengthen the therapeutic efficiency without cross-resistance, and had mild adverse effects, especially the mild cardiac toxicity of THP and neurotoxicity of NVB, which tended to improve the quality of life of patients and was conducive for consolidation therapy in the later stage. (3) Alternately applying chemotherapy regimens of CHOPE, MAED, MMED, TAED, improved SMILE, middle-dose cytarabine and L-asparaginase and Hyper-CVAD in the consolidation phase after remission induction was able to reduce the drug resistance of tumor cells. (4) Patients were admitted to the sterile laminar flow ward as soon as possible to receive supportive treatment, avoiding chemotherapy-related death. (5) The number of courses was appropriately prolonged, where it was above 8 in the first year, and 4--6 and 2--3 in the second and third years, respectively. Subsequent outpatient follow-up and regular recheck were conducted to achieve close monitoring and timely treatment.

Nevertheless, the present study is not without limitations. It was a small, single-center, retrospective, cohort study. Further large, randomized, and controlled studies are required to confirm whether this strategy can be considered as an optimized treatment regimen in initial treatment of young ENKTL patients. The patients in this study may have received many different chemotherapy regimens over time, and this is likely to have an influence on the efficacy of the regimens studied here. In addition, the wide variety of regimens may confound the results, so strictly controlled prospective trials are necessary. Finally, patients with active systemic EBV infection received ganciclovir and foscarnet, which could bias the results.

Conclusions
===========

These results suggest improved OS, PFS, DFS, and relapse rate in young patients with ENKTL receiving \>8 courses of high-intensity chemotherapy.

Supplementary Files
===================

###### 

Description of each patient.

  No   Sex/age (years)   Stage   Total chemotherapy courses   Treatments (number and types)                                    Outcome    Follow-up (months)
  ---- ----------------- ------- ---------------------------- ---------------------------------------------------------------- ---------- --------------------
  1    M/23              III     3                            2 CHOP, 1 SMILE                                                  Dead       11
  2    M/25              I       4                            2 CHOP, 2 SMILE                                                  Survival   42
  3    M/32              II      3                            1 CHOP, 1 SMILE, 1 CHOPE                                         Dead       30
  4    M/42              II      4                            2 CHOP, 2 SMILE                                                  Dead       36
  5    M/42              I       3                            2 CHOP, 1 SMILE                                                  Dead       60
  6    M/52              I       3                            1 CHOP, 1 SMILE, 1 CHOPE                                         Dead       62
  7    M/57              II      3                            2 CHOP, 1 CHOPE                                                  Dead       24
  8    M/55              I       3                            1 CHOP, 1 SMILE, 1 CHOPE                                         Dead       38
  9    F/49              II      5                            2 CHOP, 2 SMILE, 1 CHOPE                                         Dead       40
  10   F/18              I       3                            1 CHOP, 1 SMILE, 1 CHOPE                                         Dead       48
  11   M/46              II      4                            1 CHOP, 1 SMILE, 2 CHOPE                                         Survival   55
  12   F/49              I       3                            1 CHOP, 1 SMILE, 1 CHOPE                                         Survival   73
  13   M/27              IV      3                            2 CHOP, 1 SMILE                                                  Dead       8
  14   F/38              II      4                            2 CHOP, 1 SMILE, 1 CHOPE                                         Dead       26
  15   M/41              I       7                            3 CHOP, 2 SMILE, 2 CHOPE                                         Survival   47
  16   M/49              II      7                            3 CHOP, 1 SMILE, 3 CHOPE                                         Dead       34
  17   M/48              III     8                            3 CHOP, 2 SMILE, 3 CHOPE                                         Dead       17
  18   F/57              I       8                            3 CHOP, 2 SMILE, 3 CHOPE                                         Survival   29
  19   M/59              III     6                            2 CHOP, 2 SMILE, 2 CHOPE                                         Dead       31
  20   F/25              II      8                            2 CHOP, 3 SMILE, 3 CHOPE                                         Survival   44
  21   M/42              II      8                            4 CHOP, 2 SMILE, 2 CHOPE                                         Dead       28
  22   M/52              II      8                            3 CHOP, 3 SMILE, 2 CHOPE                                         Survival   66
  23   F/20              I       6                            4 CHOP, 1 SMILE, 1 CHOPE                                         Survival   33
  24   M/35              I       6                            2 CHOP, 2 SMILE, 2 CHOPE                                         Dead       55
  25   M/38              I       6                            2 CHOP, 2 SMILE, 2 CHOPE                                         Survival   80
  26   M/39              II      6                            3 CHOP, 1 SMILE, 2 CHOPE                                         Survival   29
  27   F/48              I       6                            4 CHOP, 1 SMILE, 1 CHOPE                                         Dead       42
  28   M/48              I       6                            2 CHOP, 2 SMILE, 2 CHOPE                                         Survival   59
  29   F/44              I       6                            3 CHOP, 2 SMILE, 1 CHOPE                                         Dead       61
  30   M/50              II      6                            3 CHOP, 1 SMILE, 2CHOPE                                          Dead       32
  31   F/50              I       6                            4 CHOP, 1 SMILE, 1 CHOPE                                         Survival   47
  32   M/49              IV      6                            4 CHOP, 1 SMILE, 1 CHOPE                                         Dead       12.5
  33   F/49              II      9                            2 CHOP, 2 SMILE, 1 CHOPE, 2 MAED, 2 MMED                         Dead       55
  34   F/51              I       12                           3 CHOP, 2 SMILE, 2 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD            Survival   38
  35   F/52              I       12                           4 CHOP, 2 SMILE, 1 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD            Survival   20
  36   M/54              II      11                           3 CHOP, 1 SMILE, 2 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD            Dead       58
  37   M/57              II      10                           2 CHOP, 2 SMILE, 1 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD            Survival   15
  38   F/57              II      14                           3 CHOP, 2 SMILE, 2 CHOPE, 3 MAED, 2 MMED, 1 HyperCVAD, 1 EPOCH   Survival   40
  39   M/57              I       13                           3 CHOP, 2 SMILE, 1 CHOPE, 1 EPOCH, 3 MAED, 2 MMED, 1 HyperCVAD   Survival   37.5
  40   F/59              III     12                           2 CHOP, 3 SMILE, 2 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD            Dead       66
  41   M/40              I       12                           4 CHOP, 2 SMILE, 1 CHOPE, 1 MAED, 2 MMED, 1 EPOCH, 1 HyperCVAD   Survival   25
  42   M/18              I       9                            3 CHOP, 1 SMILE, 2 CHOPE, 2 MAED, 1 MMED                         Dead       65
  43   M/24              I       12                           2 CHOP, 2 SMILE, 2 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD, 1 EPOCH   Survival   63
  44   M/28              I       14                           4 CHOP, 2 SMILE, 2 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD, 1 EPOCH   Survival   33
  45   F/28              I       14                           2 CHOP, 2 SMILE, 2 CHOPE, 4 MAED, 2 MMED, 1 HyperCVAD, 1 EPOCH   Survival   67
  46   M/31              I       14                           3 CHOP, 2 SMILE, 2 CHOPE, 3 MAED, 2 MMED, 2 HyperCVAD            Survival   68
  47   F/35              II      14                           4 CHOP, 2 SMILE, 2 CHOPE, 2 MAED, 2 MMED, 2 EPOCH                Dead       66
  48   F/42              II      12                           3 CHOP, 1 SMILE, 2 CHOPE, 3 MAED, 2 MMED, 1 HyperCVAD            Survival   66
  49   F/43              II      11                           3 CHOP, 2 SMILE, 1 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD            Dead       36
  50   F/49              II      12                           2 CHOP, 2 SMILE, 1 CHOPE, 3 MAED, 3 MMED, 1 HyperCVAD            Survival   44
  51   F/59              II      12                           3 CHOP, 1 SMILE, 2 CHOPE, 3 MAED, 2 MMED, 1 EPOCH                Survival   54.5
  52   F/52              III     14                           5 CHOP, 2 SMILE, 2 CHOPE, 1 MAED, 2 MMED, 2 HyperCVAD            Dead       40
  53   F/54              II      14                           3 CHOP, 3 SMILE, 2 CHOPE, 3 MAED, 2 MMED, 1 HyperCVAD            Survival   46
  54   M/28              I       14                           3 CHOP, 2 SMILE, 2 CHOPE, 4 MAED, 3 MMED                         Survival   30
  55   F/49              I       14                           3 CHOP, 1 SMILE, 2 CHOPE, 3 MAED, 3 MMED, 1 HyperCVAD, 1 EPOCH   Survival   64
  56   F/50              I       14                           5 CHOP, 3 SMILE, 1 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD            Survival   34
  57   M/48              I       14                           2 CHOP, 2 SMILE, 2 CHOPE, 4 MAED, 3 MMED, 1 HyperCVAD            Survival   80
  58   M/55              I       14                           3 CHOP, 3 SMILE, 2 CHOPE, 3 MAED, 2 MMED, 1 HyperCVAD            Survival   78
  59   M/57              I       14                           3 CHOP, 2 SMILE, 1 CHOPE, 3 MAED, 3 MMED, 1 HyperCVAD, 1EPOCH    Survival   82
  60   M/38              I       14                           2 CHOP, 2 SMILE, 2 CHOPE, 4 MAED, 3 MMED, 1 HyperCVAD            Survival   49
  61   M/25              I       14                           3 CHOP, 3 SMILE, 2 CHOPE, 3 MAED, 2 MMED, 1 HyperCVAD            Survival   44
  62   M/26              I       14                           2 CHOP, 3 SMILE, 2 CHOPE, 4 MAED, 2 MMED, 1 HyperCVAD            Survival   37
  63   M/49              I       14                           3 CHOP, 2 SMILE, 2 CHOPE, 3 MAED, 2 MMED, 1 HyperCVAD, 1 EPOCH   Survival   31
  64   M/53              II      12                           3 CHOP, 2 SMILE, 3 CHOPE, 1 MAED, 2 MMED, 1 HyperCVAD            Dead       30
  65   M/57              III     9                            3 CHOP, 2 SMILE, 2 CHOPE, 1 MAED, 1 MMED                         Dead       26
  66   M/59              II      10                           3 CHOP, 2 CHOPE, 1 MAED, 2 MMED, 2 HyperCVAD                     Dead       34
  67   M/59              IV      9                            3 CHOP, 3 SMILE, 2 MAED, 1 MMED                                  Dead       15.5
  68   M/59              IV      9                            2 CHOP, 2 SMILE, 1 CHOPE, 2 MAED, 1 HyperCVAD, 1 EPOCH           Dead       14
  69   M/44              II      10                           2 CHOP, 2 SMILE, 1 CHOPE, 2 MAED, 2 MMED, 1 HyperCVAD            Dead       21

###### 

Kaplan-Meier curve for 5-year overall survival (**A**), progression-free survival (**B**), and event-free survival (**C**) of different clinical stages.
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###### 

Clinical characteristics of patients.

  Characteristics                                                              High-intensity (n=37)   6--8 courses (n=18)   \<6 courses (n=14)   P (comparison between the three groups)   P (high-intensity group *vs.* \<6 courses group)
  ---------------------------------------------------------------------------- ----------------------- --------------------- -------------------- ----------------------------------------- --------------------------------------------------
  Age (years), median (range)                                                  49 (18--59)             48 (20--59)           42 (18--57)          0.822                                     0.584
  Gender, n (%)                                                                                                                                   0.698                                     0.423
   Male                                                                        22 (59.5%)              12 (66.7%)            10 (71.4%)                                                     
   Female                                                                      15 (40.5%)              6 (33.3%)             4 (28.6%)                                                      
  B symptoms, n (%)                                                                                                                               0.950                                     0.891
   Yes                                                                         11 (29.7%)              6 (33.3%)             4 (28.6%)                                                      
   No                                                                          26 (70.3%)              12 (66.7%)            10 (71.4%)                                                     
  Performance status, n (%)                                                                                                                       0.981                                     0.947
   ECOG 0--1                                                                   31 (83.8%)              15 (83.3%)            12 (85.7%)                                                     
   ECOG 2                                                                      6 (16.2%)               3 (16.7%)             2 (14.3%)                                                      
  LDH \>UNV[\*](#tfn1-medscimonit-22-4297){ref-type="table-fn"}, n (%)                                                                            0.811                                     0.576
   Yes                                                                         9 (24.3%)               3 (16.7%)             3 (21.4%)                                                      
   No                                                                          28 (75.7%)              15 (83.3%)            11 (78.6%)                                                     
  Ann Arbor Stage, n (%)                                                                                                                          0.996                                     0.985
   I                                                                           19 (51.4%)              9 (50.0%)             6 (42.9%)                                                      
   II                                                                          13 (35.1%)              6 (33.3%)             6 (42.9%)                                                      
   III                                                                         3 (8.1%)                2 (11.1%)             1 (7.1%)                                                       
   IV                                                                          2 (5.4%)                1 (5.6%)              1 (7.1%)                                                       
  IPI score, n (%)                                                                                                                                0.851                                     0.685
   0--1                                                                        27 (73.0%)              13 (72.2%)            9 (64.3%)                                                      
   2                                                                           7 (18.9%)               3 (16.7%)             2 (14.3%)                                                      
   3                                                                           1 (2.7%)                1 (5.6%)              2 (14.3%)                                                      
   4--5                                                                        2 (5.4%)                1 (5.6%)              1 (7.1%)                                                       
  NK/T-cell PI score \[[@b39-medscimonit-22-4297]\], n (%)                                                                                        NA                                        0.997
   0                                                                           10 (27.0%)              5 (27.8%)             3 (21.4%)                                                      
   1                                                                           12 (32.4%)              6 (33.3%)             5 (35.7%)                                                      
   2                                                                           8 (21.6%)               4 (22.2%)             3 (21.4%)                                                      
   3--4                                                                        7 (18.9%)               3 (16.7%)             3 (21.4%)                                                      
  EBV infection[\*\*](#tfn2-medscimonit-22-4297){ref-type="table-fn"}, n (%)                                                                      0.887                                     0.916
   Negative                                                                    25 (67.6%)              13 (72.2%)            9 (64.3%)                                                      
   Positive                                                                    12 (32.4%)              5 (27.8%)             5 (35.7%)                                                      
  Nodal involvement, n (%)                                                                                                                        0.879                                     0.618
   Yes                                                                         14 (37.8%)              8 (44.4%)             6 (42.9%)                                                      
   No                                                                          23 (62.2%)              10 (55.6%)            8 (57.1%)                                                      
  Primary sites involvement, n (%)                                                                                                                0.889                                     0.700
   Nasal cavity                                                                27 (73.0%)              12 (66.7%)            10 (71.4%)                                                     
   Other sites                                                                 10 (27.0%)              6 (33.3%)             4 (28.6%)                                                      
  Ki-67 index, n (%)                                                                                                                              0.883                                     0.657
   ≤6%                                                                         17 (46.0%)              7 (38.9%)             6 (42.9%)                                                      
   \>60%                                                                       20 (54.1%)              11 (61.1%)            8 (57.1%)                                                      

The normal upper limit of LDH is 300 IU/L, LDH \>300 IU/L refers to elevation;

EBV infection is indicated by \>10^3^ IU/ml. NA -- not applicable.

###### 

Short-term efficacy and EBV infection.

  Group            EBV+ (%)       EBV-- (%)       P               
  ---------------- -------------- --------------- --------------- -------
  High-intensity   CR             41.7% (5/12)    88.0% (22/25)   0.006
  PR               25.0% (3/12)   4.0% (1/25)     0.091           
  RR               66.7% (8/12)   92.0% (23/25)   0.073           
  6--8 courses     CR             40.0% (2/5)     76.9% (10/13)   0.268
  PR               20.0% (1/5)    7.7% (1/13)     0.490           
  RR               60.0% (3/5)    84.6% (11/13)   0.533           
  \<6 courses      CR             40.0% (2/5)     77.8% (7/9)     0.266
  PR               20.0% (1/5)    11.1% (1/9)     NA              
  RR               60.0% (3/5)    88.9% (8/9)     0.505           

RR -- remission rate; CR -- complete remission; PR -- partial remission.

###### 

Survival rate in patients with and without EBV infection.

  Survival     High-intensity (n=37)   6--8 courses (n=18)   \<6 courses (n=14)   All                                                      
  ------------ ----------------------- --------------------- -------------------- ------ ------ ------- ------ ----- ------- ------ ------ ---------
  5-year OS    80.5                    32.1                  0.010                51.3   26.7   0.294   41.7   0.0   0.221   62.2   23.1   \<0.001
  5-year PFS   72.2                    0.0                   \<0.001              50.0   0.0    0.101   20.8   0.0   0.505   54.7   19.7   \<0.001

OS -- overall survival; PFS -- progression-free survival.

###### 

Multivariate analysis of factors affecting OS, PFS, and EFS in patients with ENKTL.

  Factors                      OS      PFS     EFS                                                                 
  ---------------------------- ------- ------- ----------------- ------- ------- ----------------- ------- ------- -----------------
  Total chemotherapy courses   0.004   0.494   (0.303, 0.803)    0.004   0.497   (0.307, 0.803)    0.010   0.547   (0.346, 0.864)
  Chemotherapy strategy        0.006   0.495   (0.301, 0.816)    0.008   0.511   (0.312, 0.837)    0.017   0.558   (0.346, 0.900)
  NK score                     0.001   5.731   (2.208, 14.877)   0.000   6.258   (2.375, 16.488)   0.000   6.824   (2.415, 19.279)

OS -- overall survival; PFS -- progression-free survival; EFS -- event-free survival; RR -- relative risk; CI -- confidence interval.

###### 

Adverse effects.

  Grade 3--4 adverse effects       High-intensity (n=37)   6--8 courses (n=18)   \<6 courses (n=14)   Overall P
  -------------------------------- ----------------------- --------------------- -------------------- -----------
  Aleucocytosis                    364 (79.8%)             94 (78.3%)            31 (64.6%)           0.051
  Anemia                           148 (32.5%)             28 (23.3%)            12 (25.0%)           0.111
  Thrombocyopenia                  130 (28.5%)             23 (19.2%)            9 (18.8%)            0.057
  Neutrocytopenia                  320 (70.2%)             74 (61.7%)            28 (58.3%)           0.075
  Nausea and vomit                 74 (16.2%)              13 (10.8%)            3 (6.3%)             0.08
  Dysfunction of liver             12 (2.6%)               0                     0                    0.105
  Dysfunction of kidney            0                       0                     0                    
  Alopecia                         14 (3.1%)               4 (3.3%)              0                    0.457
  Cardiac damage                   0                       0                     0                    
  Peripheral neuritis              0                       0                     0                    
  Oral ulcer                       74 (16.2%)              12 (10.0%)            5 (10.4%)            0.159
  Neutropenia with fever           49 (10.7%)              13 (10.8%)            4 (8.3%)             0.87
  Interventions                                                                                       
  Red blood cell transfusion                                                                          
   Single patient                  17 (45.9%)              6 (34.3%)             4 (28.5%)            0.442
   One course                      10 (27.0%)              3 (16.6%)             2 (14.1%)            0.512
  Platelet transfusion                                                                                
   Single patient                  8 (21.6%)               3 (17.1%)             2 (13.9%)            0.805
   One course                      3 (8.1%)                1 (5.3%)              4.80%                0.943
  Antibiotics                                                                                         
   Single patient                  64.90%                  50.00%                42.50%               0.298
   One course                      24.30%                  16.10%                13.20%               0.66
  Chemotherapy-related mortality   0                       0                     0                    
  Acute pancreatitis               12 (2.6%)               3 (2.5%)              1 (2.1%)             0.973
  Hypofibrinogenemia               345 (75.7%)             80 (66.7%)            31 (64.6%)           0.055
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